{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:26:14Z","timestamp":1787167574091,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, with the increase of antibiotic resistance, tigecycline has attracted much attention as a new broad-spectrum glycylcycline antibiotic. It is widely used in the treatment of complex skin and soft tissue infections, complex abdominal infections and hospital-acquired pneumonia by inhibiting bacterial protein synthesis. Tigecycline can exhibit significant time-dependent bactericidal activity, and its efficacy is closely related to pharmacokinetics. It can be evaluated by the ratio of AUC0-24 to the minimum inhibitory concentration (MIC) of pathogens. However, tigecycline may cause nausea, vomiting, diarrhea and a few patients have elevated serum aminotransferase, especially in critically ill patients. The safety of patients still needs further study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, the clinical data of 263 patients with pulmonary infection in Shengjing Hospital of China Medical University and the Second Affiliated Hospital of Dalian Medical University were collected retrospectively, and the hepatotoxicity prediction model was established. The potential correlation between the toxic and side effects of tigecycline and the number of hospitalization days was preliminarily discussed, and the correlation analysis between the number of hospitalization days and continuous variables was established. Finally, the deep learning model was used to predict the hospitalization days of patients through simulated blood drug concentration and clinical laboratory indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The degree of abnormal liver function was significantly correlated with AST, GGT, MCHC and hospitalization days. Secondly, the correlation between hospitalization time and clinical test indexes and simulated drug concentration was analyzed. It was found that multiple clinical laboratory parameters of patients (such as EO #, HCT, HGB, MCHC, PCT, PLT, WBC, AST, ALT, Urea), first dose (Dose), age and APACHE II score were significantly correlated with hospitalization days. The simulated blood drug concentration was correlated with the length of hospital stay from 12\u202fh after administration, and reached the strongest between 24 and 48\u202fh. The AUC of the liver function prediction model can reach 0.90. Further analysis showed that there was a potential correlation between hepatotoxicity and hospitalization days. The median hospitalization days of patients in the non-hepatotoxicity group, liver function injury group and hepatotoxicity group were 20, 23, and 30\u202fdays, respectively. Based on these results, the length of hospital stay was predicted by the deep learning prediction model with an error within 1\u202fday.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, the hospitalization days of infected patients were predicted by deep learning model with low error. It was found that it was related to clinical test parameters, hepatotoxicity and dosage after administration. The results provided an important reference for the clinical application of tigecycline, and emphasized the need to pay attention to its toxic and side effects in use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2024.1512091","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:29:36Z","timestamp":1734434976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Prediction and analysis of toxic and side effects of tigecycline based on deep learning"],"prefix":"10.3389","volume":"15","author":[{"given":"Yin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.neubiorev.2015.05.001","article-title":"Perceptual inference","volume":"55","author":"Aggelopoulos","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/jac\/dkn242","article-title":"Tigecycline pharmacokinetic\/pharmacodynamic update","volume":"62","author":"Ap","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.31083\/j.fbl2703099","article-title":"Deep learning quantification of vascular pharmacokinetic parameters in mouse brain tumor models","volume":"27","author":"Arledge","year":"2022","journal-title":"Front. Biosci."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1086\/431676","article-title":"The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data","volume":"41","author":"Babinchak","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S315","DOI":"10.1086\/431673","article-title":"In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections","volume":"41","author":"Bradford","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfac101","volume-title":"Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling","author":"Chou","year":"2023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s11096-019-00912-5","article-title":"Tigecycline-induced coagulopathy: a literature review","volume":"41","author":"Cui","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.7150\/thno.90246","article-title":"Deep learning for automatic organ and tumor segmentation in nanomedicine pharmacokinetics","volume":"14","author":"Dhaliwal","year":"2024","journal-title":"Theranostics"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1086\/431675","article-title":"The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/FTD.0000000000000784","article-title":"Safety and efficacy of Tigecycline in intensive care unit patients based on therapeutic drug monitoring","volume":"42","author":"Fan","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e9961","DOI":"10.1097\/MD.0000000000009961","article-title":"High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study","volume":"97","author":"Geng","year":"2018","journal-title":"Medicine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jgar.2016.12.016","article-title":"Epidemiology of multidrug-resistant gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients","volume":"9","author":"Gupta","year":"2017","journal-title":"J. Glob. Antimicrob. Resistan."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1002\/cam4.5203","article-title":"Characteristics and in-hospital outcomes of elderly patients with cancer in a top-ranked hospital in China, 2016-2020: real-world study","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6153041","DOI":"10.1155\/2019\/6153041","article-title":"Artificial intelligence in interventional radiology: a literature review and future perspectives","volume":"2019","author":"Iezzi","year":"2019","journal-title":"J. Oncol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.12669\/pjms.38.6.5872","article-title":"Effects of Tigecycline combined with Cefoperazone on bacterial clearance and serum biochemical indexes in patients with pulmonary infections in ICU","volume":"38","author":"Li","year":"2022","journal-title":"Pak. J. Med. Sci."},{"key":"ref19","author":"Liu","year":"2024"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"102804","DOI":"10.1016\/j.isci.2021.102804","article-title":"Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens","volume":"24","author":"Lu","year":"2021","journal-title":"iScience"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1083464","DOI":"10.3389\/fphar.2023.1083464","article-title":"Population pharmacokinetics of tigecycline in critically ill patients","volume":"14","author":"Luo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2146\/ajhp150894","article-title":"Tigecycline-induced coagulopathy","volume":"74","author":"McMahan","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jconrel.2022.11.014","article-title":"Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics","volume":"352","author":"Ota","year":"2022","journal-title":"J. Control. Release"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000001078","article-title":"Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing","volume":"45","author":"Poweleit","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","article-title":"Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder","volume":"47","author":"Sabanis","year":"2015","journal-title":"Infect. Dis."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijid.2005.05.003","article-title":"Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial","volume":"9","author":"Sacchidanand","year":"2005","journal-title":"Int. J. Infect. Dis."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1128\/AAC.01636-05","article-title":"Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections","volume":"50","author":"Van Wart","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e00345-17","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of Tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/jcph.236","article-title":"Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects","volume":"54","author":"Yamashita","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","article-title":"Risk factors for tigecycline-induced hypofibrinogenaemia","volume":"45","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1512091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:29:39Z","timestamp":1734434979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2024.1512091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":30,"alternative-id":["10.3389\/fmicb.2024.1512091"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2024.1512091","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"article-number":"1512091"}}